Carlsmed (NASDAQ:CARL) Shares Up 0.5% - What's Next?

Key Points

• Carlsmed shares rose 0.5% to $15.02, with trading volume about 10% above its daily average. The stock’s 200-day moving average is $12.45, versus a 50-day average of $15.01.
• Analyst sentiment is broadly positive: four analysts rate the stock a Buy, one a Hold and one a Sell, producing a “Moderate Buy” consensus and an average price target of $19.50.
• Carlsmed beat quarterly EPS expectations by $0.01, reporting a loss of $0.39 per share and $18.94 million in revenue. Despite strong liquidity, the company remains unprofitable, with a negative net margin of 57.42% and analysts expecting a full-year loss.

Carlsmed, Inc. (NASDAQ:CARL - Get Free Report)'s share price rose 0.5% during trading on Monday. The company traded as high as $15.66 and last traded at $15.02. 93,674 shares traded hands during trading, an increase of 10% from the average daily volume of 84,905 shares. The stock had previously closed at $14.95.

Analyst Upgrades and Downgrades

CARL has been the topic of several research reports. Truist Financial raised their target price on Carlsmed from $18.00 to $20.00 and gave the company a "buy" rating in a research report on Thursday, August 6th. Weiss Ratings upgraded Carlsmed from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, August 11th. Wall Street Zen raised Carlsmed from a "sell" rating to a "hold" rating in a research note on Saturday, August 15th. Finally, BTIG Research raised their price objective on Carlsmed from $23.00 to $24.00 and gave the company a "buy" rating in a report on Monday, October 12th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Carlsmed currently has an average rating of "Moderate Buy" and an average price target of $19.50.

Carlsmed Stock Up 0.5%

The stock has a market capitalization of $410.05 million, a price-to-earnings ratio of -10.50 and a beta of 2.09. The business's 50-day moving average is $15.01 and its two-hundred day moving average is $12.45. The company has a quick ratio of 8.66, a current ratio of 8.84 and a debt-to-equity ratio of 0.18.

Carlsmed (NASDAQ:CARL - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.01. The company had revenue of $18.94 million during the quarter. Carlsmed had a negative net margin of 57.42% and a negative return on equity of 38.06%. Equities analysts anticipate that Carlsmed, Inc. will post -1.50 EPS for the current year.

Institutional Investors Weigh In On Carlsmed

Large investors have recently made changes to their positions in the stock. Jupiter Topco LLC acquired a new position in Carlsmed during the second quarter worth $12,992,000. Parkman Healthcare Partners LLC purchased a new stake in Carlsmed in the 2nd quarter valued at $6,200,000. BlackRock Inc. purchased a new stake in Carlsmed in the 2nd quarter valued at $5,528,000. KCM Capital Inc acquired a new stake in shares of Carlsmed in the 1st quarter worth $1,810,000. Finally, Janus Henderson Group PLC increased its stake in shares of Carlsmed by 7.6% in the 1st quarter. Janus Henderson Group PLC now owns 1,227,452 shares of the company's stock worth $11,108,000 after acquiring an additional 86,834 shares during the last quarter.

Carlsmed Company Profile

Carlsmed, Inc is a medical technology company focused on personalized solutions for spine surgery. The company combines patient-specific planning, advanced imaging, software and additive manufacturing to develop implants designed to address the anatomical needs of individual patients.

Its products include the aprevo® patient-specific interbody implant system, which is designed for use in spinal fusion procedures. Carlsmed's technology is intended to support surgeons in planning procedures and selecting or creating implants that may help restore spinal alignment and improve surgical precision.

Carlsmed serves the spine-care market through relationships with spine surgeons, hospitals and other healthcare providers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.